Abstract
Modification of the terminal tails of histones is considered one of the documented mechanisms for epigenetic control of gene expression. Histone deacetylase inhibitors (HDACi) lead to a state of hyperacetylation of histone, a condition that can affect normal gene transcription. Furthermore, HDACi have many other protein targets involved in regulation of gene expression, cell proliferation and cell death. For these properties some HDACi are nowadays used as anticancer drugs with promising results. Several molecules with HDACi properties (valproic acid, trichostatin A, apicidin, MS-275, sodium butyrate, boric acid, salicylic acid) have been found to induce congenital malformations associated with hyperacetylation of histones in the target organs. Cell death is the major event in the target organs a few hours after embryonic exposure to HDACi. Gene deregulation, oxidative stress, DNA demethylation, and/or retinoic acid imbalance are the modes of action postulated for HDACi-induced teratogenesis.
Keywords: HDAC inhibitors, teratogenesis, congenital malformations, mechanisms.
Current Pharmaceutical Design
Title:Teratogenic Activity of HDAC Inhibitors
Volume: 20 Issue: 34
Author(s): Erminio Giavini and Elena Menegola
Affiliation:
Keywords: HDAC inhibitors, teratogenesis, congenital malformations, mechanisms.
Abstract: Modification of the terminal tails of histones is considered one of the documented mechanisms for epigenetic control of gene expression. Histone deacetylase inhibitors (HDACi) lead to a state of hyperacetylation of histone, a condition that can affect normal gene transcription. Furthermore, HDACi have many other protein targets involved in regulation of gene expression, cell proliferation and cell death. For these properties some HDACi are nowadays used as anticancer drugs with promising results. Several molecules with HDACi properties (valproic acid, trichostatin A, apicidin, MS-275, sodium butyrate, boric acid, salicylic acid) have been found to induce congenital malformations associated with hyperacetylation of histones in the target organs. Cell death is the major event in the target organs a few hours after embryonic exposure to HDACi. Gene deregulation, oxidative stress, DNA demethylation, and/or retinoic acid imbalance are the modes of action postulated for HDACi-induced teratogenesis.
Export Options
About this article
Cite this article as:
Giavini Erminio and Menegola Elena, Teratogenic Activity of HDAC Inhibitors, Current Pharmaceutical Design 2014; 20 (34) . https://dx.doi.org/10.2174/1381612820666140205144900
DOI https://dx.doi.org/10.2174/1381612820666140205144900 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Apoptosis Inducing Effects of Thymus Linearis Methanolic Extract in HCT-116 Cells and LC-MS Chemical Profiling of Its Active Constituents
The Natural Products Journal PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets A Guide to Treatment of Sarcoidosis
Current Drug Therapy Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design Recognition and Function of HumanγδT Cells: Application for Tumor Immunotherapy
Current Immunology Reviews (Discontinued) Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma
Current Pharmaceutical Design Detection of Formation of Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles Based on its Optical Properties
Current Nanoscience Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry Editorial: Advances in Epithelial Ovarian Cancer Therapy
Current Pharmaceutical Design APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Risk of Drug Resistance and Repeated Infection with <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in Intensive Care Unit Cancer Patients
Combinatorial Chemistry & High Throughput Screening Effect of Intravitreal Injection of Aflibercept on Cardiovascular Risk Parameters in Patients with Neovascular Age-Related Macular Degeneration
Current Reviews in Clinical and Experimental Pharmacology Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Current Pharmaceutical Design